Nothing Special   »   [go: up one dir, main page]

ES2158284T3 - Metil-fenil-oxazolidinonas quirales. - Google Patents

Metil-fenil-oxazolidinonas quirales.

Info

Publication number
ES2158284T3
ES2158284T3 ES96902871T ES96902871T ES2158284T3 ES 2158284 T3 ES2158284 T3 ES 2158284T3 ES 96902871 T ES96902871 T ES 96902871T ES 96902871 T ES96902871 T ES 96902871T ES 2158284 T3 ES2158284 T3 ES 2158284T3
Authority
ES
Spain
Prior art keywords
methyl
quiral
oxazolidinones
phenyl
atomos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96902871T
Other languages
English (en)
Inventor
Henry Laurent
Eckhard Ottow
Gerald Kirsch
Helmut Wachtel
Herbert Schneider
Daryl Faulds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2158284T3 publication Critical patent/ES2158284T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DERIVADOS DE LA (R) (-) METIL FENIL OXAZOLIDINONA DE FORMULA (I), SU PREPARACION Y USO EN MEDICAMENTOS EN LOS QUE R ES UN RADICAL DE HIDROCARBONO DE HASTA 5 ATOMOS DE C.
ES96902871T 1995-10-20 1996-02-09 Metil-fenil-oxazolidinonas quirales. Expired - Lifetime ES2158284T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19540475A DE19540475A1 (de) 1995-10-20 1995-10-20 Chirale Methylphenyloxazolidinone

Publications (1)

Publication Number Publication Date
ES2158284T3 true ES2158284T3 (es) 2001-09-01

Family

ID=7776217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96902871T Expired - Lifetime ES2158284T3 (es) 1995-10-20 1996-02-09 Metil-fenil-oxazolidinonas quirales.

Country Status (25)

Country Link
US (1) US6025376A (es)
EP (1) EP0859766B1 (es)
JP (1) JPH11513693A (es)
KR (1) KR100417359B1 (es)
CN (1) CN1077103C (es)
AT (1) ATE201203T1 (es)
AU (1) AU715344B2 (es)
CZ (1) CZ292167B6 (es)
DE (2) DE19540475A1 (es)
DK (1) DK0859766T3 (es)
ES (1) ES2158284T3 (es)
FI (1) FI980862A0 (es)
GR (1) GR3036305T3 (es)
HK (1) HK1015788A1 (es)
HU (1) HUP9802630A3 (es)
IL (1) IL117091A (es)
NO (1) NO310772B1 (es)
NZ (1) NZ301645A (es)
PL (1) PL185526B1 (es)
PT (1) PT859766E (es)
RU (1) RU2156243C2 (es)
SK (1) SK282653B6 (es)
TR (1) TR199800679T2 (es)
WO (1) WO1997015561A1 (es)
ZA (1) ZA961074B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009965A2 (en) * 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
DE19928312A1 (de) * 1999-06-16 2000-12-21 Schering Ag Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1216700A1 (de) * 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsysteme (TDS) enthaltend (R)-(-)-Methylphenyloxazolidinon-Derivate, Inhibitoren der Phosphodiesterase IV
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc MULTIPLE WAVELENGTH ILLUMINATOR
JP2005519928A (ja) * 2002-02-04 2005-07-07 ハース，ベルナー Ｃｏ放出能力を有する化合物の投与によって哺乳動物を治療する方法と、ｃｏ放出能力を有する化合物ならびにその医薬組成物
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
WO2004098592A1 (ja) * 2003-05-06 2004-11-18 Senju Pharmaceutical Co. Ltd. オキサゾリジノン誘導体含有組成物
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
WO2017106138A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Oxazolidinones as taro inhibitors
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019193091A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
DE2655369A1 (de) * 1976-12-03 1978-06-08 Schering Ag 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
DE3639225A1 (de) * 1986-11-14 1988-05-19 Schering Ag Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
US5420154A (en) * 1990-08-03 1995-05-30 Smithkline Beecham Corp. TNF inhibitors
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5227369A (en) * 1991-07-11 1993-07-13 The Regents Of The University Of California Compositions and methods for inhibiting leukocyte adhesion to cns myelin
CA2117547A1 (en) * 1992-02-24 1993-09-02 Michiko Watanabe Ice nucleus-forming bacterium, process for cultivation of the same, ice nucleus-forming substance containing the same, and uses of said substance
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis

Also Published As

Publication number Publication date
US6025376A (en) 2000-02-15
IL117091A0 (en) 1996-06-18
EP0859766B1 (de) 2001-05-16
EP0859766A1 (de) 1998-08-26
DK0859766T3 (da) 2001-08-13
DE19540475A1 (de) 1997-04-24
NO981688L (no) 1998-04-15
NO981688D0 (no) 1998-04-15
GR3036305T3 (en) 2001-10-31
HUP9802630A2 (hu) 1999-04-28
IL117091A (en) 2000-07-26
PL326322A1 (en) 1998-09-14
SK282653B6 (sk) 2002-11-06
FI980862A (fi) 1998-04-17
CZ120198A3 (cs) 1998-07-15
HK1015788A1 (en) 1999-10-22
FI980862A0 (fi) 1998-04-17
CN1077103C (zh) 2002-01-02
SK49598A3 (en) 1998-09-09
HUP9802630A3 (en) 2000-01-28
PT859766E (pt) 2001-10-30
JPH11513693A (ja) 1999-11-24
NZ301645A (en) 1999-11-29
NO310772B1 (no) 2001-08-27
RU2156243C2 (ru) 2000-09-20
TR199800679T2 (xx) 1998-07-21
CZ292167B6 (cs) 2003-08-13
PL185526B1 (pl) 2003-05-30
ZA961074B (en) 1997-02-26
CN1200115A (zh) 1998-11-25
DE59606920D1 (de) 2001-06-21
KR100417359B1 (ko) 2004-03-19
AU715344B2 (en) 2000-01-20
KR19990064339A (ko) 1999-07-26
ATE201203T1 (de) 2001-06-15
AU4712396A (en) 1997-05-15
WO1997015561A1 (de) 1997-05-01

Similar Documents

Publication Publication Date Title
ES2158284T3 (es) Metil-fenil-oxazolidinonas quirales.
FI910034A0 (fi) 3-aminopiperidinderivat och liknande kvaeve innehaollande heterocykler.
AR023289A1 (es) COMPUESTOS CON ACTIVIDAD INHIBIDORA DE ENDOPEPTIDASA NEUTRA (NEP), COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y PROCEDIMIENTO PARA SU PREPARACIoN.
NO2009014I2 (no) ulipristalacetat
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
DK162090C (da) 3-acyl-2-oxindol-1-carboxamid-forbindelser samt 2-oxindol-1-carboxamid-forbindelser til anvendelse som mellemprodukter
TR199901674T2 (es)
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
ES2114931T3 (es) Nuevos esteres esteroidales.
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
BR9711586A (pt) Compostos e uso dos mesmo
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0474712T3 (da) Anvendelse af lysolecitinderivater til fremstilling af et farmaceutisk præparat
FI894061A (fi) Menetelmä lääkeaineina käyttökelpoisten , -disubstituoitujen N-sykloalkyylialkyylibentsyyliamiinien valmistamiseksi ja niiden synteesivälituotteita
ES2038623T3 (es) Procedimiento para preparar soluciones de oxazafosforinas con estabilidad mejorada.
AR247744A1 (es) Compuestos organosilano y catalizadores que contienen dichos compuestos
ES2091310T3 (es) Nuevos derivados de la n-benzoil-prolina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FI922806A (fi) Substituerade 4-fenyl-4 -piperidinkarboxamider med baode lokalbedoevande och smaertstillande effekt samt foerfaranden foer deras framstaellning.
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
DK4687A (da) Anvendelse af esterforbindelser som temporaert mikrobicid
DK319785A (da) Acetyleniske phenoxypropanolderivater
DK591787A (da) Anvendelse af 5-(substitueret phenyl)-oxa-zolidinonderivater til fremstilling af et til behandling af depressioner egnet laegemiddel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 859766

Country of ref document: ES